Multicenter, open-label safety study of serlopitant in adults for the treatment of pruritus associated with prurigo nodularis, atopic dermatitis, or psoriasis.
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2018
Price : $35 *
At a glance
- Drugs Serlopitant (Primary)
- Indications Pertussis
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2018 According to Menlo Therapeutics media release, study is fully enrolled, and the Company expects to report top-line data in December 2018.
- 04 Apr 2018 New trial record